XOMA Royalty Corp (XOMA) USD0.0075

Sell:$21.50Buy:$29.30$0.53 (2.13%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$21.50
Buy:$29.30
Change:$0.53 (2.13%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$21.50
Buy:$29.30
Change:$0.53 (2.13%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

XOMA Royalty Corporation is a biotechnology royalty aggregator. The Company’s royalty aggregator business is primarily focused on early to mid-stage clinical assets, primarily in Phase I and II, with significant commercial sales potential that are licensed to larger pharmaceutical partners. The Company has a portfolio of economic rights and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The Company's royalty portfolio includes OJEMDA (tovorafenib), JNJ-63723283 (cetrelimab), RZ358, arimoclomol, mezagitamab (TAK-079), acimtamig (AFM13), AB054, ficlatuzumab (AV-299), COM902, vosaroxin, aldoxorubicin, INCAGN02385, INCAGN02390, MNPR-101, PBF-680, PBF-677, PBF-999, PBF-1129, PBF-1650, RZ402, DSUVIA (sufentanil sublingual tablet), IXINITY [coagulation factor IX (recombinant)], CMP-001 (vidutolimod), NTM-1631, NTM-1634, NTM-1633, NTM-1632, NIR178, MK-4830, AFM24, INCAGN01949, AB101, and CFZ533 (iscalimab).

Key people

Owen P. Hughes
Chief Executive Officer, Director
Thomas Burns
Chief Financial Officer, Senior Vice President - Finance
Bradley J. Sitko
Chief Investment Officer
Jack L. Wyszomierski
Independent Chairman of the Board
Heather L. Franklin
Independent Director
Natasha A. Hernday
Independent Director
Barbara A. Kosacz
Independent Director
Joseph M. Limber
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US98419J2069
  • Market cap
    $293.15m
  • Employees
    13
  • Shares in issue
    11.78m
  • Exchange
    NASDAQ
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.